Amylyx IPO

amylyx.com

Amylyx is a pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases.

Founded2014
Total Funding to Date$203.25MM
Register for Details

For more details on financing and valuation for Amylyx, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Amylyx Ticker Symbol

Amylyx does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

Amylyx Stock Price

The stock price for Amylyx will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Amylyx Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
7/20/2021 Series C-1 and C-2 $541.01MM $XXX.XX $XXX.XX
7/1/2020 Series B $477.95MM $XXX.XX $XXX.XX
8/23/2016 Series A $22.09MM $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Other companies like Amylyx in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$317.32MM
Sector
 
 
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$334.19MM